Unfortunately, recent advances in targeted chemotherapy have not benefited patients with retinoblastoma because our knowledge is limited regarding the signaling pathways affected following the inactivation of the retinoblastoma gene RB1. Also, retinoblastoma clinical trials take years to complete because so few patients are available. The gene discussed is RB1; the disease is retinoblastoma.